B cell tolerance checkpoint function in multiple sclerosis and transient CD52 depletion

Anastasia Alexaki[1], Fotis Baltoumas[2], Dimitrios Tzanetakos[3], Chrysoula Zografou[4], Chrysoula Michaletou[1], Galini Kyriakaki[1], Aglaia G. Vakrakou[1], Maria Anagnostouli[1], Georgia Karadima[1], Marianna Tzanoudaki[5], Marinos C. Dalakas[1,6], Leonidas Stefanis[1], Konstantinos Kilidireas[1], Kevin C. O'Connor[7], Georgios Pavlopoulos[2], Panos Stathopoulos[1*].

1. First Department of Neurology, National and Kapodistrian University of Athens, Greece.

2. Institute for Fundamental Biomedical Research, Biomedical Science Research Center 'Alexander Fleming', Vari, Greece.

3. Second Department of Neurology, National and Kapodistrian University of Athens, Greece.

4. MABY, Monoclonal Antibody Discovery, Biomedical Science Research Center 'Alexander Fleming', Vari, Greece.

5. Specialized and Referral Center for Primary Immunodeficiencies and Pediatric Immunology, 'Agia Sophia' Children's Hospital, Athens, Greece.

6. Neuroimmunology Unit, Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.

7. Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, USA.

*Corresponding author: Panos Stathopoulos, First Department of Neurology, National and Kapodistrian University of Athens, Papadiamantopoulou 21, 11518 Athens, Greece. Email: pmstathopoulos@gmail.com; panosst@eginitio.uoa.gr.

Abstract

Objective: To assess the effect of transient CD52-positive immune cell depletion with alemtuzumab, used to treat patients with relapsing-remitting multiple sclerosis (RRMS), on B cell tolerance mechanisms.

Methods: To evaluate peripheral B cell tolerance checkpoint integrity in patients and controls, we constructed 128 recombinant mAbs from single mature naïve B cells and tested their poly- and autoreactivity. We examined three healthy donors (HDs), three immunotherapy-naïve MS patients, and six patients treated with alemtuzumab at comparable time points post-treatment (mean ± SD 3.8 ± 0.39 years). Moreover, we investigated B cell receptor (BCR) repertoire parameters associated with tolerance mechanisms in the same subject groups.

Results: Polyreactive and autoreactive fraction means did not differ significantly among the three subgroups. In patients treated with alemtuzumab however, a bimodal distribution was noted: three of six patients had a high fraction of autoreactive mAbs, likely pointing to a defective peripheral checkpoint, while three had an autoreactive fraction significantly lower than that of HDs (P=0.027). Presence of secondary autoimmunity did not correlate with this bimodal distribution. In BCR repertoire analysis, alemtuzumab-treated patients showed lower mean naïve complementarity-determining region 3 (CDR3) net charge than HDs (P=0.036).

Interpretation: Extraordinarily low fraction of autoreactive mature naive B cells in half of alemtuzumab-treated patients did not correlate with clinical parameters and therefore likely reflects stochastic variation in the context of immune reconstitution. Observations in the described setting may also apply

in other immune reconstitution therapies like cladribine and B cell depleting therapies.

Key words: Multiple sclerosis; alemtuzumab; B cell tolerance; secondary autoimmunity.

Abbreviations: AIRE, Autoimmune Regulator; BCR, B Cell Receptor; CBA, Cell-Based Assay; CDR3, Complementarity-Determining Region 3, GFP, Green Fluorescent Protein; HDs, Healthy Donors; Hep-2, Human Epithelial Cells Type 2; IgH, Immunoglobulin Heavy Chain; IgK, Immunoglobulin Kappa Light Chain; IgL, Immunoglobulin Lambda Light Chain, IRTs, Immune Reconstitution Therapies; MS, Multiple Sclerosis; mAb, Monoclonal Antibody; NGS, Next-Generation Sequencing; PBMCs, Peripheral Blood Mononuclear Cells; RRMS, Relapsing-Remitting Multiple Sclerosis; SHMs, Somatic Hypermutations; SLE, Systemic Lupus Erythematosus; T1D, Type 1 Diabetes; Tregs, Regulatory T Cells; TSHR, Thyroid-Stimulating Hormone Receptor

Introduction

Multiple sclerosis (MS), the most common autoimmune disease of the central nervous system[1], is pathologically characterized by demyelination, acute and chronic inflammation, and axonal and neuronal degeneration[2]. MS is associated with genetic and non-genetic risk factors[3,4], and, from a clinical standpoint, has been historically classified into subtypes, the more common being relapsing-remitting MS (RRMS)[5].

The high clinical efficacy of anti-CD20 therapies has highlighted the crucial role of B cells in disease pathogenesis[6]. Physiologically, as B cells mature in the bone marrow, V(D)J gene recombination generates the necessary B cell receptor (BCR) diversity to shield against infection but at the same time also autoreactive BCRs. These are removed by two tolerance checkpoints: the central, between the pre-B to immature B cell transition, and the peripheral, between the new emigrant to mature naive B cell transition. Defects in checkpoint function have been found in almost all autoimmune diseases examined[7]. In RRMS, a defective central (in 2 out of 7 patients) and mainly a defective peripheral tolerance checkpoint (in 7 out of 7 patients) have been demonstrated[8].

A critical question is whether tolerance defects can be reversed with targeted immunotherapy. In type 1 diabetes (T1D), treatment with the anti-CD20 monoclonal antibody (mAb) rituximab could not restore peripheral checkpoint function[9]. In contrast to continuous immunotherapy, immune reconstitution therapies (IRTs, alemtuzumab, cladribine, autologous hemopoietic stem cell

transplantation) promote drug-free disease remission[10]. The mAb alemtuzumab targets CD52+ immune cells (T and B cells, monocytes, natural killer (NK) cells, eosinophils and dendritic cells) causing their temporary depletion and renewal within weeks, months, or years, depending on the cell type. Clinically, alemtuzumab is very effective in diminishing MS disease activity, however its application is limited by frequent development of secondary autoimmune phenomena, most commonly thyroid-related[11].

CD52+ B cell depletion differs from CD20+ B cell depletion. First, CD52, but not CD20, is expressed on pre-B cells[12], and accordingly anti-CD52 therapy affects a deeper depletion of B cells. Second, CD52—but not CD20 depletion—is followed by the generation of a high frequency of naïve B cells that exceeds baseline levels[13]. To better understand efficacy and side effects of alemtuzumab, as well as B cell implication in RRMS and secondary autoimmunity, we evaluated the impact of alemtuzumab on B cell tolerance mechanisms. We first assessed the peripheral B cell tolerance checkpoint integrity with a validated method involving cloning of individual mature naïve B cells and examination of their poly- and autoreactivity. Next, we inquired whether next-generation sequencing (NGS)[14] of the BCR can identify alterations in tolerance mechanisms present in either immunotherapy-naïve RRMS patients or in patients treated with alemtuzumab. Finally, we examined if tolerance parameters correlate with clinical outcomes.

Materials and Methods

Patients, specimens, study protocol approval and patient consents

Peripheral blood was collected from healthy donors (HDs) and RRMS patients (immunotherapy-naïve or treated with alemtuzumab) after obtaining informed consent. Patients were diagnosed[15], treated with alemtuzumab (12 mg/day iv for 5 consecutive days, followed one year later by 12 mg/day for 3 days), and followed at Eginitio University Hospital; blood samples were collected at least one year after the second treatment cycle. The three groups (HDs, immunotherapy-naïve RRMS and alemtuzumab-treated patients) were matched for age and sex. The study protocol and consents were approved by the Institutional Review Board of Eginitio Hospital. Two of the three healthy donor specimens (HD01 and HD02), were processed previously in the Laboratory of Dr. O'Connor at Yale University[16].

PTPN22 R620W/C1858T variant genotyping

A previously described[17] protocol was applied. Briefly, DNA extraction from whole blood (Qiagen) was followed by PCR amplification of the R620W/C1858T variant-containing PTPN22 region (Thermo Fisher Scientific, Integrated DNA Technologies) and Sanger sequencing.

B cell isolation, staining and single-cell sorting

A previously established[17,18] protocol was followed. Briefly, cryopreserved PBMCs were thawed, and B cells were positively selected using a biotin antibody cocktail with magnetic streptavidin nanobeads (MojoSort human pan B cell isolation kit, BioLegend). The isolated B cells were stained with anti-human CD10, CD19, CD27 (BioLegend), IgM, CD21, and IgG (BD

Biosciences). Single mature naïve B cells (IgM^+, IgG^-, $CD21^+$, $CD27^-$, $CD19^+$, $CD10^-$) were then sorted into 96-well plates using a FACSAria flow cytometer and immediately frozen on dry ice and stored until further use.

mAb production

An established[17] approach was used. For each B cell, matching heavy (IgH) and light (IgK and IgL) chain variable immunoglobulin regions were amplified, cloned into expression vectors, sequenced, and analyzed with IgBlast (http://www.ncbi.nlm.nih.gov/projects/igblast). HEK 293A cells were then co-transfected with the heavy and light chain vectors, and the supernatant was applied to polyreactivity and, as purified IgG, autoreactivity ELISAs and the thyroid stimulating hormone receptor (TSHR) live cell-based assay (CBA). Each mAb was cloned, expressed and tested in duplicate.

ELISA

Established[17,18] protocols were followed. Briefly, mAb concentrations were determined in HEK supernatants by sandwich ELISA using anti-human IgG antibodies (Jackson Laboratories). Supernatants were tested for polyreactivity, defined as reactivity against three different antigens: dsDNA, LPS, and insulin (all by Sigma-Aldrich). Autoreactivity was determined by application of purified mAbs to microplates precoated with human epithelial cell lysate (QUANTA Lite, INOVA Diagnostics).

Live CBA for the detection of Thyroid-Stimulating Hormone Receptor (TSHR) antibodies

A previously described CBA was used[19]. In brief, HEK 293T cells were transfected with a plasmid vector encoding human TSHR-GFP (TSHR -Green Fluorescent Protein; kind gift from MABY and Dr. Bieberman of Charite University Hospital). Transfected cells were then incubated with 2 µg/mL of mAb, and subsequently with a secondary, Alexa fluor 647-labeled anti-human IgG antibody (1:1000, Jackson Laboratories). Fluorescence was measured with a BD FACS Canto cytometer. Positivity was assessed by calculating the delta mean fluorescence intensity (ΔMFI) index with FlowJo v10 (BD). The commercial anti-human TSHR mAb clone m22 (ABCDY antibodies, kind gift from MABY) served as a positive control. The cutoff for positivity was applied at the control mean + 4SDs.

cDNA libraries construction and BCR sequencing

RNA was isolated from PBMCs with the QIAwave RNA Mini Kit (Qiagen). cDNA libraries were prepared with the New England Biolabs Human Next® Immune Sequencing Kit[14]. Reverse transcription employed biotin-labeled primers and addition of a unique molecular identifier (UMI). cDNA was purified using streptavidin magnetic beads, and IgH and IgK/IgL or just IgH variable regions were amplified by a series of two PCRs. DNA libraries were pooled equimolarly, followed by high throughput paired-end sequencing on either the Illumina MiSeq or NextSeq.

Raw data quality control

Quality control was performed using a slightly modified pRESTO workflow[14]. First, reads with a mean Phred quality score >20 and without a valid C-region

primer were discarded. Both IgH and IgK/IgL primers were used to improve sampling and increase the number of analyzed reads. Reads with identical UMIs were categorized into a single consensus sequence. If multiple isotypes were identified within a single UMI read group, the consensus sequence was generated using only the reads assigned to the majority isotype. UMI consensus sequence mate-pairs were initially assembled de novo into full-length Ig sequences, requiring a minimum overlap length of 8 bp, a maximum error rate of 0.3, and a p-value threshold of $1 \times 10^{-}$□. Mate-pairs that could not be assembled de novo were instead aligned to the 202248-3 release of the International Immunogenetics Information System (IMGT) V-segment germlines, with a minimum identity threshold of 0.5 and an E-value cutoff of $1 \times 10^{-}$□. A secondary isotype assignment was performed by aligning the tail of the UMI consensus sequences to a set of sequences anticipated to be upstream of the C region primer. These reference sequences were derived from the IMGT C region and J segment consensus database. Following preprocessing, V(D)J germline segments were assigned, using the IgBLAST search algorithm[20].

BCR repertoire analysis

Reported germline sequences, combined with the C-region annotation, were used to define the locus and isotype. IgBLAST results were parsed and standardized using ChangeO[14], and filtered to include only productive BCR sequences. Genotyping was performed using TIgGER[14]. Germline sequences of each assigned clonal group were identified using Change-O. The genotyped, clonal-assigned reads were used to calculate somatic

hypermutations (SHMs) with SHazaM, by comparing observed sequences against the germline. With the SHM frequencies calculated, a 1% (of nucleotides) mutational cutoff was set to separate naive and memory BCRs (for both IgH and IgK/IgL). V- and J-gene (IgH and IgK/IgL) family usage was calculated as the percentage of unique sequences assigned to a given gene family within the total number of sequences for each isotype in each compartment (naïve/memory). Variations in the usage of IgK V-gene sequences were evaluated by calculating the proportion of upstream (distal) vs. downstream (proximal) V-gene families. The definition of IgK V-gene sequences as upstream or downstream was based on annotations provided by IMGT. IgH CDR3 properties[14,21] (amino acid sequence length, hydrophobicity -estimated as the grand average hydropathy index, or GRAVY-, net charge, polarity, acid chain bulkiness, aliphatic index, as well as the ratios of aromatic, acidic, and basic amino acid residues) were measured separately for naive and memory sequences using Alakazam[14].

Statistical analysis

Data were plotted and analyzed with the GraphPad Prism software version 8.3.1. Unpaired t-tests and one-way ANOVA tests were performed to compare means between different groups.

Results

Study subjects and production of mAbs

Study subjects included five healthy donors, four immunotherapy-naive RRMS patients, and nine alemtuzumab-treated RRMS patients (**Table**). Age and sex distribution did not differ significantly between the three patient groups. RRMS patients were sampled after an attack leading to diagnosis but prior to steroids and all tested positive for intrathecal immunoglobulin synthesis. Alemtuzumab-treated patients were sampled 3.5 to 4.8 years [mean ± standard deviation (SD) 3.8 ± 0.39 years] post treatment initiation, so length of follow-up and degree of immune reconstitution at the time of sampling were comparable between treated patients. Six of the alemtuzumab-treated patients had (at the time of sampling) suffered secondary autoimmune complications, while two patients showed evidence of MS activity post-treatment (**Table**). To assess B cell tolerance mechanisms, we produced 128 mAbs in biological duplicates from single mature naïve B cells (IgM^+, IgG^-, $CD21^+$, $CD27^-$, $CD19^+$, $CD10^-$) of 12 subjects. Sequences of the cloned variable regions were compared to the germline using IgBLAST, and mutated sequences were excluded from the analysis as previously described[18] (**Supplementary Table 1**). Importantly, carriers of the C1858T PTPN22 polymorphism, associated with defective central and peripheral B cell tolerance checkpoint function[8], were excluded from all subject groups.

<u>Polyreactive fractions of mature naïve B cells from HDs, RRMS patients, and alemtuzumab-treated RRMS patients</u>

To determine whether anti-CD52 treatment with alemtuzumab affects the frequency of polyreactive mature naïve B cells, we used an established and extensively validated experimental approach that tests reactivity of mature

naïve B cell-derived mAbs against three antigens: dsDNA, LPS, and insulin, with polyreactivity being defined as reactivity against all three antigens. The fraction of polyreactive mAbs ranged from 9% to 14.29% in HDs (mean ± SD 10.57 ± 3.24 %), from 7.29% to 12.50% in immunotherapy-naïve RRMS patients (10.9 ± 2.7%), and from 8.33% to 14.29% in patients with RRMS treated with alemtuzumab (11.5 ± 2.3%) (**Fig. 1**). Polyreactive mAb percentages did not differ significantly between the three groups.

Autoreactive fractions of mature naïve B cells from HDs, RRMS patients, and alemtuzumab-treated RRMS patients

The peripheral B cell tolerance checkpoint integrity was assessed by examining purified, mature naïve B cell-derived mAbs for potential autoreactivity, i.e. reactivity against human epithelial type two (HEp-2) cell lysate[8] (**Fig. 2**). After performing a historically validated HEp-2 ELISA, we found that the percentage of autoreactive mAbs ranged from 19.05 to 33.33% in HDs (mean ± SD 26.55 ± 7.17%), from 23.08 to 37.5% (32.7 ± 8.33%) in immunotherapy-naïve RRMS patients, and from 11.11 to 37.5% (24.18 ± 14.3%) in alemtuzumab-treated patients. Autoreactive mAb percentages did not differ significantly between the three groups.

As however 1) variance in autoreactive fractions was high and 2) determination of checkpoint integrity is dichotomous (preserved/damaged) and made on an individual subject basis, we assessed each patient separately in relation to HDs[22,23]. Previously, no overlap was observed between HD and RRMS mature naïve autoreactive fractions, however

separation was borderline (HD <30% and RRMS 33.3 to 45.5%)[7,8]. Here, overlap did occur and HD autoreactivity ranged from 19.05 to 33.33% while RRMS autoreactivity from 23.08 to 37.5%. As a consequence, we suggest that the function of the peripheral checkpoint was likely compromised in the two RRMS patients exceeding HD autoreactivity and intact in one (**Fig. 2**).

In patients treated with alemtuzumab, we observed a more contrasting bimodal distribution. In three of six patients, the percentage of autoreactive mAbs was higher than all HDs (36.36% in Ale40 and 37.50% in Ale03 and Ale33 37.50% (mean ± SD 37.12 ± 0.66%), likely pointing to defective peripheral B cell tolerance function (**Fig. 2**). In the remaining three alemtuzumab-treated RRMS patients, we observed an extraordinarily low autoreactive fraction, with percentages ranging from 8.33 to 14.29% (14.29% in Ale27, 11.11% in Ale46, and 8.33% in Ale25 (mean ± SD 11.24 ± 3%). Autoreactive fractions in this subset of patients were lower than those of HDs (range 19.05 to 33.33%, mean ± SD 26.55 ± 7.17%; P for the post-hoc comparison = 0.027) as well as those of immunotherapy-naïve RRMS patients (32.7 ± 8.33%, P for the post-hoc comparison = 0.0137). Further, comparison of Hep2 ODs between each patient and pooled HDs revealed significantly lower values in two out of the three alemtuzumab-treated patients with a low autoreactive mAb fraction (Ale 46, p = 0.0088; Ale25, p = 0.0041, **Fig.2**). In addition, such low frequencies have never been observed in HDs or RRMS patients previously[7,8]. Of the three patients with a low autoreactive mature naïve mAb/BCR fraction, one (Ale25) had manifested secondary

autoimmunity in the form of Graves' disease (**Table**); thus, a low autoreactive fraction does not preclude secondary autoimmunity.

Mature naïve-derived mAbs from RRMS patients treated with alemtuzumab do not bind Graves' disease autoantigen TSHR

Almost 50% of alemtuzumab-treated RRMS patients develop secondary, thyroid-related autoimmunity, commonly TSHR autoantibody-positive Graves' disease[11]. With that in mind, we asked whether mature naïve B cell-derived mAbs from the two RRMS patients treated with alemtuzumab that developed TSHR autoantibody-positive Graves' disease bound TSHR. Of note, only one of these two patients had a compromised peripheral B cell tolerance checkpoint. mAbs produced from mature naïve B cells of HDs, immunotherapy-naïve RRMS patients and alemtuzumab-treated patients that did not develop Graves' disease served as negative controls. A commercial mAb against the TSHR was used as a positive control[24] (**Supplementary Fig. 1**). None of the 95 mAb tested bound the TSHR (**Supplementary Table 2**), indicating that even in the one patient with defective peripheral tolerance B cell function, autoimmunity likely initiates beyond the lymphnode/T cell help stage of B cell development and not in the naïve stage, prior to the encounter of the (auto)antigen.

Exploratory analysis of naïve BCR repertoire properties as markers of tolerance

As the established approach to assess B cell tolerance is time-consuming and laborious, we sought to investigate whether BCR NGS could evaluate B cell

tolerance checkpoint integrity to a similar extent or perhaps with enhanced sensitivity. To that end, we performed BCR NGS out of total PBMC RNA for the indicated HD, immunotherapy-naïve RRMS and alemtuzumab-treated RRMS samples (**Table**). After raw data quality control, we applied a 1% mutational cutoff to separate naïve from memory IgH sequences, yielding percentages comparable[25] to immunophenotypic profiling of HDs (**Supplementary Table 3**). With that separation, we were able to reproduce known differences in CDR3 properties between memory and naïve B cells [21] (**Supplementary Fig. 2**).

Several reports[17,21,22,26,27] have indicated that IgH CDR properties might be a measure for autoreactivity and compromised B cell tolerance; therefore we examined whether these differ between in the naïve compartment of HDs, immunotherapy-naïve RRMS patients and RRMS patients treated with alemtuzumab (**Fig. 3A-D**). Of the four CDR3 properties examined, one was found to differ significantly between subgroups. Specifically, net charge was found to be lower in alemtuzumab-treated RRMS patients compared to HDs (IgD+IgM+ mean ± SD -0.49 ± 0.04 vs. -0.38 ± 0.036, P = 0.0036). We examined if CDR3 properties correlate with peripheral tolerance defects as determined by the autoreactivity ELISA; this however was not the case (**Supplementary Fig. 3**).

Next, we examined whether signs of altered secondary VJk recombination exist. Of note, VJ recombination in the Igk locus occurs in two stages: the primary, generating diversity; and the secondary, replacing autoreactive BCRs

with non-reactive ones in the context of central B cell tolerance mechanisms[28]. Increased repertoire frequency of the Jk1 gene segment has been associated with increased frequency of primary recombination, while increased frequency of the downstream Jk3,4,5 gene segments, as well as of the upstream Vk genes with increased secondary rearrangements[28,29]. Here, Jk1 frequency did not significantly differ between HDs, immunotherapy-naïve, and alemtuzumab-treated RRMS patients (**Fig. 3E**) while naïve B cell usage of upstream Vk and downstream Jk3,4,5 gene segments did not consistently separate subject groups (**Fig. 3F**).

Exploratory analysis of memory BCR repertoire properties

As a third B cell tolerance checkpoint might exist between the naïve and the memory IgM compartment[30], we examined memory B cell repertoire characteristics as well. We first analyzed CDR3 properties in the three subject groups (HDs, immunotherapy-naïve and alemtuzumab-treated RRMS) per immunoglobulin class (**Fig. 4**). Significant differences were observed in the IgD compartment. Specifically, alemtuzumab-treated RRMS patients showed a significantly increased CDR3 length (mean ± SD 16.18 ± 0.6) compared to HDs (15.07 ± 0.24; P = 0.012), while the comparison between alemtuzumab-treated and immunotherapy-naïve RRMS patients (15.6 ± 0.6) did not reach significance (P=0.112). Importantly, polarity was significantly decreased in alemtuzumab-treated patients (8.4 ± 0.1) compared to both HDs (8.6 ± 0.06; P = 0.039) and RRMS patients (8.5 ± 0.06; P = 0.045) (**Fig. 4A-D**). Taken together, these differences represent interesting findings of an exploratory analysis that warrant confirmation in larger studies.

Similar to the naïve compartment, Jk1 frequency did not differ between HDs, immunotherapy-naïve, and alemtuzumab-treated RRMS patients (**Fig. 4E**). Further, naïve B cell usage of upstream Vk and downstream Jk3,4,5 gene segments did not consistently separate subject groups (**Fig. 4F**).

Discussion

We examined B cell tolerance mechanisms in the setting of RRMS and in vivo perturbation by alemtuzumab; the effect of transient CD52+ immune cell depletion on tolerance checkpoints had not been researched before. In addition, we combined an approach used historically for analysis of B cell checkpoint function involving construction of recombinant mAbs from post-checkpoint B cells with repertoire analysis by NGS. Again, this combination had not been applied —to our knowledge— beforehand. Of particular importance, our results may be applicable not only to immune reconstitution with alemtuzumab, but also to other immune reconstitution therapies such as cladribine and B cell-targeted therapies[10].

The examination of central B cell tolerance checkpoints in individuals with autoimmune diseases indicates that these tolerance mechanisms are compromised, except in the case of MS [7]. Although we did not directly examine polyreactivity of new emigrant B cells, which defines the central checkpoint function, we examined polyreactivity of mature naïve B cells. This subset comprises the next differentiation step for B cells after new emigrant B

cells. As most polyrective B cells are removed before the new emigrant stage, with the polyreactive fraction remaining low thereafter, polyreactivity of mature naïve B cells could reflect central checkpoint integrity[17]. We found no differences in mature naive polyreactivity between HDs, immunotherapy-naïve and alemtuzumab-treated RRMS patients, and therefore one could suggest that central checkpoint function is preserved in both patient groups. In accordance, we observed no differences in the frequency of IGKJ1, as well as upstream Vκ and downstream Jκ3-4-5 gene usage among subject groups in the NGS repertoire analysis, suggesting a similar extent of secondary recombination. Of note, secondary recombination and receptor editing constitute a main mechanism of central B cell tolerance[28,31]. These collective data are in agreement with previous research, where in only two of seven MS patients was the central tolerance checkpoint compromised[8].

After performing autoreactivity ELISA with mature naïve-derived mAbs, we found the peripheral B cell tolerance checkpoint likely compromised in two out of three immunotherapy-naïve RRMS patients. Previous investigations had found the peripheral checkpoint compromised in seven out of seven untreated relapsing MS patients[8] but also that the autoreactive fraction can nearly overlap in some RRMS patients and HDs[7]. Therefore, our results are in line with these previous investigations. In alemtuzumab-treated patients, three out of six patients demonstrated high autoreactive fractions (higher than all HDs) and likely damaged peripheral tolerance checkpoint integrity, with this being theoretically attributable to both RRMS- and alemtuzumab-associated perturbation. Interestingly, the other three alemtuzumab-treated patients

showed not only preserved peripheral tolerance checkpoint function but particularly low autoreactive fractions, significantly lower than those of all HDs (and immunotherapy-naïve RRMS patients). This effect was statistically significant both on an individual basis ($P<0.01$) as well as in post-hoc group comparisons ($P<0.05$). Because these patients differed from HDs (and even more from immunotherapy-naïve RRMS patients), this effect can be attributed to CD52+ immune cell depletion with alemtuzumab. This very low autoreactivity did not correlate with secondary autoimmunity and appeared to be a random, stochastic phenomenon associated with immune reconstitution.

In some contrast (and a different setting), T1D patients treated with the anti-CD20 mAb rituximab did not regain function of the defective peripheral B cell tolerance checkpoint[9]. The differential action of rituximab and alemtuzumab could be explained by deeper depletion of B cells by alemtuzumab but also—and perhaps more so—by effective depletion of T cells including Tregs, known to influence peripheral checkpoint function[7,32]. Specifically, defective Tregs have been connected to defective peripheral B cell tolerance checkpoint function in both MS and IPEX, an inherited condition with FOXP3 deficiency[7,32,33]. In further support, Treg function is restored[34,35] post alemtuzumab application.

We additionally investigated whether defects in peripheral tolerance can directly lead to secondary autoimmunity, which often targets the thyroid in the form of Graves' disease and anti-TSHR antibodies[11]. We therefore tested mature naïve-derived mAbs against TSHR by CBA, however none of the

tested mAbs showed binding with TSHR. Although we did not find evidence that TSHR autoantibody generation is a pre-germinal center event, this cannot be excluded since autoantigen-specific B cells are rare.

The IgH CDR3 region plays a critical role in determining specificity toward antigens as well as repertoire diversity. Therefore, its composition and distinct physicochemical properties are of interest in the study of autoimmunity and may correlate with B cell tolerance defects[14,16,36,37]. Previous studies examining autoimmune B cell repertoires have shown that IgH CDR3 regions of patients are longer[17,38], more hydrophobic[39], and more positively charged[40] compared to controls. Here, we found that in the naïve compartment of alemtuzumab-treated RRMS patients CDR3 net charge is significantly lower than in HDs, an effect that can be attributed to RRMS, alemtuzumab treatment, or both. Of interest and potential biological significance was also the fact that while CDR3s were of shorter length in HD memory (primarily IgM) vs. naïve cells as previously reported[21], they tended to be longer in the RRMS vs. HD naïve compartment (**Supplementary Fig. 2** and **Fig. 3**, respectively). As IgM memory B cells and plasma cells tend to be less poly- and autoreactive[30,41] (perhaps as a result of affinity maturation and selection pressure), longer naïve CDR3s in RRMS may represent a sensitive marker of promiscuity/polyreactivity. Indeed, such antibody/B cell promiscuity has been reported previously[42–45] in RRMS mAbs, serum and CSF.

Because memory cells likely play a critical role in MS immunology[46] and as a third B cell tolerance checkpoint might exist between the naïve and the

memory IgM compartment[30], we also examined whether memory IgH CDR3 properties differ between HDs and immunotherapy-naïve or alemtuzumab-treated RRMS patients. Indeed, we found significant differences in IgD CDR3 length, and polarity between alemtuzumab-treated RRMS patients and HDs. Specifically, both RRMS and more so alemtuzumab treatment was associated with longer CDR3s. Interestingly, a similar effect was observed in RA patients treated with rituximab, where treatment was associated with longer IgD memory CDR3s and a lower IgD memory mutation acquisition rate[47]. Therefore, the increase in CDR3 length might have different etiologies in RRMS and in alemtuzumab-treated RRMS. In the latter case of alemtuzumab –similarly to the case of rituximab–, it likely is the transient B cell depletion leads to a repopulation similar to ontogeny, known to be associated with longer CDR3s[48].

Conclusion

We conducted a study whose main strength is the simultaneous, in-depth analysis of B cell reactivity and BCR repertoire diversity in an in vivo perturbed setting of drug-induced immune reconstitution. The simultaneous measurement in the same subjects allowed for examination of correlation of the two parameters examined. Importantly, our findings may apply to immune reconstitution approaches beyond alemtuzumab such as cladribine and B cell-depleting therapies. Moreover, our study of disease and treatment mechanisms was performed with human samples and did not rely on animal models. Weaknesses include lack of longitudinal pre- and post-treatment

samples, as alemtuzumab's application in our center was stopped due to a less favorable risk/benefit ratio compared to other treatments of RRMS such as B cell depletion. We compensated this lack with thorough matching cases with controls in regard to disease activity, sample acquisition time point, sex, and age. Finally, our BCR NGS experiments are of an exploratory nature and warrant confirmation in larger studies.

Our investigations show for the first time that transient CD52+ immune cell depletion could likely have a beneficial influence on peripheral B cell tolerance checkpoint function in some patients. This mechanistic line of evidence may contribute to the explanation of alemtuzumab efficacy in RRMS. Secondary autoimmunity targeting the thyroid (up to the time of sample acquisition) did not correlate with any of the measured B cell parameters and likely is a post-germinal center effect as conspicuous memory B cell expansions co-appear with autoimmune events[49]. Overall, our results illuminate both RRMS immunopathology as well as CD52-mediated immune reconstitution. Beneficial effects of alemtuzumab on B cell tolerance checkpoint function provide mechanistic support for potentially combining CD20+ with CD52+ immune cell depletion and reconstitution[50] as well as more generally targeting B and T cells, as in cladribine-mediated immune reconstitution therapy.

Data availability

Anonymized data will be shared to any qualified investigator by the corresponding author upon reasonable request.

Acknowledgments

The authors thank NEB for providing a Next® Immune Sequencing Kit, Chen Song of NEB for her valuable assistance with next generation sequencing quality control, Drs. Steven Kleinstein and Gisela Gabernet of Yale University for valuable discussions, Dr. Sofia Grammenoudi from the BSRC Fleming cell sorting core facility for her support, and Dr. A. Goules from the Department of Pathophysiology of the National and Kapodistrian University of Athens for providing bacterial culture resources.

Funding

The study was funded by the Onassis Foundation.

Competing Interests

Anastasia Alexaki, Fotis Baltoumas, Georgios Pavlopoulos and Panos Stathopoulos have received research support by the Onassis Foundation. Dimitrios Tzanetakos, Panos Stathopoulos, Leonidas Stefanis, and Konstantinos Kilidireas participated in the phase IV trial of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of MS (GZ402673-OBS13434). Chrysoula Zografou, Panos Stathopoulos, and Kevin O'Connor are founders of MABY. Galini Kyriakaki, Aglaia G. Vakrakou, Chrysoula Michaletou, Maria Anagnostouli, Georgia Karadima, Marianna Tzanoudaki, Marinos C. Dalakas: nothing to disclose.

References

1. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016;172(1):3-13.

2. Pitt D, Lo CH, Gauthier SA, et al. Toward Precision Phenotyping of Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9(6):e200025.

3. Alfredsson L, Olsson T. Lifestyle and Environmental Factors in Multiple Sclerosis. Cold Spring Harb Perspect Med. 2019;9(4):a028944.

4. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):eaav7188.

5. Ntranos A, Lublin F. Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space. Curr Neurol Neurosci Rep. 2016;16(10):90.

6. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234.

7. Meffre E, O'Connor KC. Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev. 2019;292(1):90-101.

8. Kinnunen T, Chamberlain N, Morbach H, et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest. 2013;123(6):2737-2741.

9. Chamberlain N, Massad C, Oe T, Cantaert T, Herold KC, Meffre E. Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest. 2016;126(1):282-287.

10. Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol. 2020;16(1):56-62.

11. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-1839.

12. Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006;12(23):7174-7179.

13. Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurology. 2017;74(8):961-969.

14. Vander Heiden JA, Stathopoulos P, Zhou JQ, et al. Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing. J Immunol. 2017;198(4):1460-1473.

15. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2018;17(2):162-173.

16. Lee JY, Stathopoulos P, Gupta S, et al. Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Ann Clin Transl Neurol. 2016;3(6):443-454.

17. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301(5638):1374-1377.

18. Cotzomi E, Stathopoulos P, Lee CS, et al. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain. 2019;142(6):1598-1615.

19. Stathopoulos P, Chastre A, Waters P, et al. Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity. J Immunol. 2019;202(8):2210-2219.

20. Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 2013;41(Web Server issue):W34-40.

21. Wu YC, Kipling D, Leong HS, Martin V, Ademokun AA, Dunn-Walters DK. High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. Blood. 2010;116(7):1070-1078.

22. Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med. 2005;201(10):1659-1667.

23. Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005;201(5):703-711.

24. Sanders J, Evans M, Premawardhana LDKE, et al. Human monoclonal thyroid stimulating autoantibody. Lancet. 2003;362(9378):126-128.

25. Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell subpopulations from infancy to adulthood. Clin Exp Immunol. 2010;162(2):271-279.

26. Shiokawa S, Mortari F, Lima JO, et al. IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. J Immunol. 1999;162(10):6060-6070.

27. Bridges SL, Lee SK, Johnson ML, et al. Somatic mutation and CDR3 lengths of immunoglobulin kappa light chains expressed in patients with rheumatoid arthritis and in normal individuals. J Clin Invest. 1995;96(2):831-841.

28. Nemazee D. Mechanisms of central tolerance for B cells. Nat Rev Immunol. 2017;17(5):281-294.

29. Mensah KA, Chen JW, Schickel JN, et al. Impaired ATM activation in B cells is associated with bone resorption in rheumatoid arthritis. Sci Transl Med. 2019;11(519):eaaw4626.

30. Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC, Wardemann H. A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med. 2006;203(2):393-400.

31. Halverson R, Torres RM, Pelanda R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nat Immunol. 2004;5(6):645-650.

32. Kinnunen T, Chamberlain N, Morbach H, et al. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood. 2013;121(9):1595-1603.

33. Janssen E, Morbach H, Ullas S, et al. Dedicator of cytokinesis 8-deficient patients have a breakdown in peripheral B-cell tolerance and defective regulatory T cells. J Allergy Clin Immunol. 2014;134(6):1365-1374.

34. Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med. 2011;17(6):673-675.

35. Haas J, Würthwein C, Korporal-Kuhnke M, et al. Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment. Front Immunol. 2019;10.

36. Xu JL, Davis MM. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity. 2000;13(1):37-45.

37. Stathopoulos P, Kumar A, Heiden JAV, Pascual-Goñi E, Nowak RJ, O'Connor KC. Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis. Ann N Y Acad Sci. 2018;1412(1):154-165.

38. Larimore K, McCormick MW, Robins HS, Greenberg PD. Shaping of human germline IgH repertoires revealed by deep sequencing. J Immunol. 2012;189(6):3221-3230.

39. Meffre E, Schaefer A, Wardemann H, Wilson P, Davis E, Nussenzweig MC. Surrogate light chain expressing human peripheral B cells produce self-reactive antibodies. J Exp Med. 2004;199(1):145-150.

40. Richardson C, Chida AS, Adlowitz D, et al. Molecular Basis of 9G4 B Cell Autoreactivity in Human Systemic Lupus Erythematosus. J Immunol. 2013;191(10):4926-4939.

41. Scheid JF, Mouquet H, Kofer J, Yurasov S, Nussenzweig MC, Wardemann H. Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells. Proc Natl Acad Sci U S A. 2011;108(44):18044-18048.

42. Quintana FJ, Farez MF, Viglietta V, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proceedings of the National Academy of Sciences. 2008;105(48):18889-18894.

43. Brändle SM, Obermeier B, Senel M, et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci U S A. 2016;113(28):7864-7869.

44. Willis SN, Stathopoulos P, Chastre A, Compton SD, Hafler DA, O'Connor KC. Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins. Front Immunol. 2015;6:600.

45. Quintana FJ, Farez MF, Izquierdo G, Lucas M, Cohen IR, Weiner HL. Antigen microarrays identify CNS-produced autoantibodies in RRMS. Neurology. 2012;78(8):532-539.

46. Jelcic I, Nimer FA, Wang J, et al. Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. Cell. 2018;175(1):85-100.e23.

47. Muhammad K, Roll P, Einsele H, Dörner T, Tony HP. Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment. Arthritis Rheum. 2009;60(8):2284-2293.

48. Souto-Carneiro MM, Sims GP, Girschik H, Lee J, Lipsky PE. Developmental changes in the human heavy chain CDR3. J Immunol. 2005;175(11):7425-7436.

49. Ruck T, Barman S, Schulte-Mecklenbeck A, et al. Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. Brain. 2022;145(5):1711-1725.

50. Meltzer E, Campbell S, Ehrenfeld B, et al. Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e868.

Table. Characteristics of study subjects

Samples	Age range[1]	Sex	Time to sampling[2]	MS activity	Secondary autoimmunity	Tolerance assay	Defective peripheral checkpoint	BCR NGS
HD01[3]	26-30	F	NA	NA	NA	Yes	No	No
HD02[3]	46-50	M	NA	NA	NA	Yes	No	No
HD13	31-35	F	NA	NA	NA	No	NA	Yes
HD18	36-40	F	NA	NA	NA	Yes	No	Yes
HD19	41-45	M	NA	NA	NA	No	NA	Yes
RRMS09	46-50	F	NA	NA	NA	No	NA	Yes
RRMS16	41-45	F	NA	NA	NA	Yes	Yes	Yes
RRMS17	26-30	F	NA	NA	NA	Yes	Yes	Yes
RRMS21	26-30	M	NA	NA	NA	Yes	No	Yes
Ale27	36-40	F	3.9	No	No	Yes	No	Yes
Ale40	36-40	F	3.6	No	No	Yes	Yes	Yes
Ale46	31-35	F	3.9	No	No	Yes	No	No
Ale03	36-40	M	3.9	No	Yes (Graves)	Yes	Yes	Yes
Ale25	26-30	F	3.7	No	Yes (Graves)	Yes	No	Yes
Ale26	51-55	F	3.8	No	Yes (Hashimoto)	No	NA	Yes
Ale33	36-40	M	3.5	No	Yes (Hashimoto)	Yes	Yes	No
Ale24	41-45	M	3.5	Yes	Yes (ITP, neutropenia, Hashimoto)	No	NA	Yes
Ale29	36-40	M	4.8	Yes	Yes (ITP)	No	NA	Yes

[1]Age range at the time of sample acquisition. [2]Time to sampling in years was defined as the interval between initial dose of alemtuzumab and collection of the sample. [3]Studied by the laboratory of KC O'Connor at Yale University[16]. None of the subjects carried the PTPN22 R620W polymorphism. Ale: Alemtuzumab-treated RRMS patients; F: Female; HD: Healthy donor; ITP: Immune Thrombocytopenia; M: Male; NA: Not applicable; RRMS: Relapsing-remitting multiple sclerosis.

Figure legends

Figure 1. Mature naïve B cell polyreactivity. **(A)** Mature naïve B cell-derived mAbs from 3 HDs, 3 immunotherapy-naïve and 6 alemtuzumab-treated RRMS patients were tested for their reactivity against dsDNA, LPS, and insulin by ELISA. ODs are shown on the y axis and mAbs concentrations on the x axis. Solid lines connect OD values of each mAb at a given dilution, and each point represents the mean of biological duplicates. Dotted curves represent positive control mAb ED38 binding; horizontal dotted lines represent the positivity cutoff. Below, black-filled areas of pie charts indicate the frequency of polyreactive mAbs for each subject, while the number in the center of each pie chart indicates the number of cloned mAbs per subject. (**B)** Polyreactivity frequencies in HDs, immunotherapy-naïve and alemtuzumab-treated RRMS patents, with lines representing mean values. Means did not differ significantly. Ale: Alemtuzumab-treated RRMS patients; dsDNA: Double-stranded DNA; HD: Healthy donor; LPS: Lipopolysaccharide; mAb: monoclonal antibody; RRMS: Relapsing-remitting multiple sclerosis.

Figure 2. Mature naïve B cell autoreactivity. **(A)** Mature naïve B cell-derived mAbs from 3 HDs, 3 immunotherapy-naïve and 6 alemtuzumab-treated RRMS patients were tested for their reactivity against HEp-2 cell lysate. ODs are shown on the y axis and mAbs concentrations on the x axis. Solid lines connect OD values of each mAb at a given dilution, and each point represents the mean of biological duplicates. Dotted curves represent positive control mAb ED38 binding; horizontal dotted lines represent the positivity cutoff. Below, black-filled areas of pie charts indicate the frequency of autoreactive mAbs for each subject, while the number in the center of each pie chart

indicates the number of cloned mAbs per subject. **(B)** Autoreactivity frequencies in HDs, immunotherapy-naïve and alemtuzumab-treated RRMS patents, with lines representing mean values. Means did not differ significantly. Ale: Alemtuzumab-treated RRMS patients; HEp-2: Human Epithelial Type 2 cells; HD: Healthy donor; RRMS: Relapsing-remitting multiple sclerosis.

Figure 3. Next generation sequencing analysis of naïve B cell receptor repertoire. **(A-D)** IgH CDR3 properties, calculated per Ig class: **(A)** CDR3 length, **(B)** the grand average hydropathy index (GRAVY), **(C)** net charge, **(D)** polarity. Black circles represent individual HD values, black squares those of immunotherapy-naïve RRMS patients and black triangles those of alemtuzumab-treated RRMS patients. **(E-F)** Usage of Jk1, upstream Vk, and downstream Jk3,4,5 gene segments of Igk: **(E)** collective data on Jk1 gene usage frequency across all study groups, **(F)** upstream Vk gene usage frequency plotted against downstream Jk3,4,5 usage in naive B cells from all study subjects. Differences between groups (HD, immunotherapy-naïve RRMS, and alemtuzumab-treated RRMS) were tested with the Mann-Whitney test, and p values are indicated if significant (**$P \leq 0.01$; *$P \leq 0.05$). ALE: Alemtuzumab-treated RRMS patients; CDR: Complementarity-Determining Region; HD: Healthy donor; Ig: immunoglobulin; Igk: kappa light chain; IgH: heavy chain; NGS: Next-generation sequencing; RRMS: Relapsing-remitting multiple sclerosis.

Figure 4. Next generation sequencing analysis of memory B cell receptor repertoire**.** IgH CDR3 properties, calculated per Ig class: **(A)** CDR3 length, **(B)** the grand average hydropathy index (GRAVY), **(C)** net charge, **(D)** polarity. Black circles represent individual HD values, black squares those of immunotherapy-naïve RRMS patients and black triangles those of alemtuzumab-treated RRMS patients. **(E-F)** Usage of Jk1, upstream Vk, and downstream Jk3,4,5 gene segments of Igk: **(E)** collective data on Jk1 gene usage frequency across all study groups, **(F)** upstream Vk gene usage frequency plotted against downstream Jk3,4,5 usage in memory B cells from all study subjects. Differences between groups (HD, immunotherapy-naïve RRMS, and alemtuzumab-treated RRMS) were tested with the Mann-Whitney test, and p values are indicated if significant (**$P \leq 0.01$; *$P \leq 0.05$). ALE: Alemtuzumab-treated RRMS patients; CDR: Complementarity-Determining Region; HD: Healthy donor; Ig: immunoglobulin; Igk: kappa light chain; IgH: heavy chain; NGS: Next-generation sequencing; RRMS: Relapsing-remitting multiple sclerosis.


A
OD
HD01
HD02
HD18
RRMS17
RRMS16
RRMS21
Ale27
Ale40
Ale46
Ale03
Ale33
Ale25
dsDNA
LPS
Insulin
µg/ml
14.29%
21
85.71%
9.09%
11
90.91%
8.33%
12
91.67%
12.50%
8
87.50%
12.50%
8
87.50%
7.69%
13
92.31%
14.29%
7
85.71%
9.09%
11
90.91%
12.50%
8
87.50%
12.50%
8
87.50%
12.50%
8
87.50%
8.33%
12
91.67%
Non polyreactive (%)
Polyreactive (%)
B
% of polyreactivity B cell clones
HD
RRMS
ALE

A


OD
HD01
HD02
HD18
RRMS17
RRMS16
RRMS21
Ale27
Ale40
Ale46
Ale03
Ale33
Ale25
0.01
0.1
1
µg/ml
19.05%
21
80.95%
27.27%
11
72.73%
33.33%
12
66.67%
37.50%
8
62.50%
37.50%
8
62.50%
23.08%
13
76.92%
14.29%
7
85.71%
36.36%
11
63.64%
11.11%
8
89.89%
37.50%
8
62.50%
37.50%
8
62.50%
8.33%
13
91.67%
Non-HEp-2 reactive (%)
HEp-2 reactive (%)

B


% of Hep-2 autoreactivity
40
30
20
10
0
HD
RRMS
Ale

C


**
**
OD
4
3
2
1
0
HD
RRMS17
RRMS16
RRMS21
Ale27
Ale40
Ale46
Ale33
Ale03
Ale25


A
CDR3 Length
20
18
16
14
12
IgD HD
IgD RRMS
IgD ALE
IgM HD
IgM RRMS
IgM ALE
IgD+M HD
IgD+M RRMS
IgD+M ALE
B
GRAVY
-0.2
-0.4
-0.6
-0.8
C
Net charge
0.0
-0.2
-0.4
-0.6
-0.8
*
**
**
D
Polarity
8.8
8.6
8.4
8.2
E
% Jk1 usage
45
40
35
30
25
HD
RRMS
ALE
F
% of downstream Jk3,4,5 usage
20
10
0
0
1
2
3
4
5
% of upstream Vk usage
HD
RRMS
ALE


A
CDR3 length
B
GRAVY
C
Net charge
D
Polarity
E
% Jk1 usage
HD
RRMS
ALE
F
% of downstream Jk3,4,5 usage
% of upstream Vk usage
IgA HD
IgA RRMS
IgA ALE
IgD HD
IgD RRMS
IgD ALE
IgG HD
IgG RRMS
IgG ALE
IgM HD
IgM RRMS
IgM ALE
Total HD
Total RRMS
Total ALE
HD
RRMS
ALE